Skip to main content Accessibility help

Management of epistaxis in patients on novel oral anticoagulation therapy

  • J P K Ho (a1) (a2), N Bari (a3) and F Riffat (a1) (a2)



Individuals on anticoagulation therapy are at increased risk of bleeding, including epistaxis. There is a lack of available reversal agents for novel oral anticoagulation therapy.


This paper reviews the current literature on epistaxis in the context of novel oral anticoagulation use, in order to recommend guidelines on management.


A comprehensive search of published literature was conducted to identify all relevant articles published up to April 2019.


Patients on oral anticoagulation therapy are over-represented in individuals with epistaxis. Those on novel oral anticoagulation therapy were more likely to relapse compared to patients on classic oral anticoagulants or non-anticoagulated patients. Idarucizumab is an effective antidote for bleeding associated with dabigatran use. Recommendations for epistaxis management in patients on novel oral anticoagulation therapy are outlined.


Clinicians need to be aware of the potential severity of epistaxis and the increased likelihood of recurrence. High-quality studies are required to determine the efficacy and safety of andexanet alfa and ciraparantag, as well as non-specific reversal agents.


Corresponding author

Author for correspondence: Dr Joyce Ho, Department of Otolaryngology Head and Neck Surgery, Westmead Hospital, Hawkesbury Road, Westmead, New South Wales, Australia 2145 E-mail: Fax: +61 2 8890 9852


Hide All

Dr Joyce Ho takes responsibility for the integrity of the content of the paper



Hide All
1Viehweg, TL, Roberson, JB, Hudson, J. Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg 2006;64:511–18
2Douglas, R, Wormald, P-J.Update on epistaxis. Curr Opin Otolaryngol Head Neck Surg 2007;15:180–3
3Chen, BC, Viny, AD, Garlich, FM, Basciano, P, Howland, MA, Smith, SW et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol 2012;50:854–7
4Ganetsky, M, Babu, KM, Salhanick, SD, Brown, RS, Boyer, EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011;7:281–7
5Buchheit, J, Reddy, P, Connors, JM. Idarucizumab (Praxbind) formulary review. Crit Pathw Cardiol 2016;15:7781
6Buchberger, AMS, Baumann, A, Johnson, F, Peters, N, Piontek, G, Storck, K et al. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol 2018;275:2035–43
7Callejo, FJG, Martínez, CB, González, JC, Beneyto, PM, Sanz, MM, Algarra, JM. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otolaryngol 2014;65:346–54
8L'Huillier, V, Badet, C, Tavernier, L. Epistaxis complicating treatment by anti-vitamin K and new oral anticoagulants. Eur Ann Otorhinolaryngol Head Neck Dis 2018;135:231–5
9Hylek, EM, Held, C, Alexander, JH, Lopes, RD, De Caterina, R, Wojdyla, DM et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141–7
10Connolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
11Spielmann, P, Barnes, M, White, P. Controversies in the specialist management of adult epistaxis: an evidence-based review. Clin Otolaryngol 2012;37:382–9
12Thaha, M, Nilssen, E, Holland, S, Love, G, White, P. Routine coagulation screening in the management of emergency admission for epistaxis – is it necessary? J Laryngol Otol 2000;114:3840
13Sandoval, C, Dong, S, Visintainer, P, Ozkaynak, MF, Jayabose, S. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol 2002;24:47–9
14Levy, JH, Douketis, J, Weitz, JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 2018;15:273–81
15McGarry, G, Moulton, C. The first aid management of epistaxis by accident and emergency department staff. Emerg Med J 1993;10:298300
16Strachan, D, England, J. First-aid treatment of epistaxis--confirmation of widespread ignorance. Postgrad Med J 1998;74:113–14
17Lavy, J. Epistaxis in anticoagulated patients: educating an at-risk population. Br J Haematol 1996;95:195–7
18Barnes, M, Spielmann, P, White, P. Epistaxis: a contemporary evidence based approach. Otolaryngol Clin North Am 2012;45:1005–17
19Schiele, F, van Ryn, J, Newsome, C, Sepulveda, E, Park, J, Nar, H et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554–62
20Siegal, DM, Curnutte, JT, Connolly, SJ, Lu, G, Conley, PB, Wiens, BL et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24
21Ansell, JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis 2016;41:248–52
22Pollack, CV Jr, Reilly, PA, Van Ryn, J, Eikelboom, JW, Glund, S, Bernstein, RA et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 2017;377:431–41
23Ansell, JE, Bakhru, SH, Laulicht, BE, Steiner, SS, Grosso, MA, Brown, K et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost 2017;117:238–45
24Pollack, CV Jr, Reilly, PA, Bernstein, R, Dubiel, R, Eikelboom, J, Glund, S et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015;114:198205
25Glund, S, Moschetti, V, Norris, S, Stangier, J, Schmohl, M, van Ryn, J et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015;113:943–51
26Connolly, SJ, Crowther, M, Eikelboom, JW, Gibson, CM, Curnutte, JT, Lawrence, JH et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326–35
27Raval, AN, Cigarroa, JE, Chung, MK, Diaz-Sandoval, LJ, Diercks, D, Piccini, JP et al. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation 2017;135:e604–33
28Eerenberg, ES, Kamphuisen, PW, Sijpkens, MK, Meijers, JC, Buller, HR, Levi, M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation 2011;124:1573–9
29Marlu, R, Hodaj, E, Paris, A, Albaladejo, P, Crackowski, JL, Pernod, G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012;108:217–24
30Nagalla, S, Thomson, L, Oppong, Y, Bachman, B, Chervoneva, I, Kraft, W. Reversibility of apixaban anticoagulation with a four-factor prothrombin complex concentrate in healthy volunteers. Clin Transl Sci 2016;9:176–80
31Mariat, C, Alamartine, E, Masson, I, Maillard, N, Claisse, G, Delavenne, X. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J 2015;8:199201
32Chen, BC, Sheth, NR, Dadzie, KA, Basciano, P, Howland, MA, Smith, SW et al. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis 2013;62:591–4
33Di Fusco, SA, Lucà, F, Benvenuto, M, Iorio, A, Fiscella, D, D'Ascenzo, F et al. Major bleeding with old and novel oral anticoagulants: how to manage it. Focus on reversal agents. Int J Cardiol 2018;268:75–9


Management of epistaxis in patients on novel oral anticoagulation therapy

  • J P K Ho (a1) (a2), N Bari (a3) and F Riffat (a1) (a2)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.